Home › Research › Prevention trials
Multidomain therapy for Alzheimer’s disease: a scoping review of cognitive decline trials
Jared C. Roach, Gwênlyn Glusman, Molly K. Rapozo, David A. Merrill, Jennifer E. Bramen, John F. Hodes, Prabha Siddarth, Somayeh Meysami et al.. Molecular Neurodegeneration, 2025-11-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
There have been 23 studies (completed or reported as ongoing) of multidomain interventions for AD, including 19 RCTs. Of the 15 completed RCTs, 12 demonstrate benefit from their intervention in at least one arm. Although these RCTs differ widely in their parameters, the majority support the use of multidomain therapy, and show effect sizes greater than reported for unimodal therapies, including pharmaceuticals. Multidomain therapy should be the standard of care for AD. Multidomain interventions (also known as treatments) should be employed widely, early, and first-line. Treatment or prevention is likely to be most effective at early, presymptomatic stages, but is worthwhile at all stages of disease. In order to influence multiple domains, multiple modes of therapy are likely necessary in all patients. Some individual modes, such as particular lifestyle interventions, may target multiple domains. Nevertheless, most patients will benefit from multiple modes of intervention (multimodal intervention) that together target multiple domains. Standard-of-care guidelines should explicitly include multidomain interventions. Future clinical trials must be designed to iteratively improve multidomain therapies. Payors should embrace reimbursement for effective multidomain intervention, including personalized coaching.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study. This review of 23 studies reports that most completed trials of multidomain therapy showed benefit in at least one arm and argues this approach should be standard care. It is a review of existing trials, not new evidence, and does not establish that multidomain therapy cures or prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Roach, J. C., Glusman, G., Rapozo, M. K., Merrill, D. A., Bramen, J. E., Hodes, J. F., et al. (2025). Multidomain therapy for Alzheimer’s disease: a scoping review of cognitive decline trials. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-025-00912-2
Vancouver
Roach JC, Glusman G, Rapozo MK, Merrill DA, Bramen JE, Hodes JF, et al. Multidomain therapy for Alzheimer’s disease: a scoping review of cognitive decline trials. Molecular Neurodegeneration. 2025. doi:10.1186/s13024-025-00912-2. PMID: 41275266.
BibTeX
@article{roach2025-41275266,
author = {Roach, Jared C. and Glusman, Gwênlyn and Rapozo, Molly K. and Merrill, David A. and Bramen, Jennifer E. and Hodes, John F. and Siddarth, Prabha and Meysami, Somayeh and others},
title = {{Multidomain therapy for Alzheimer’s disease: a scoping review of cognitive decline trials}},
journal = {Molecular Neurodegeneration},
year = {2025},
doi = {10.1186/s13024-025-00912-2},
pmid = {41275266},
url = {https://doi.org/10.1186/s13024-025-00912-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- There have been 23 studies (completed or reported as ongoing) of multidomain interventions for AD, including 19 RCTs.
- Of the 15 completed RCTs, 12 demonstrate benefit from their intervention in at least one arm.
- Although these RCTs differ widely in their parameters, the majority support the use of multidomain therapy, and show effect sizes greater than reported for unimodal therapies, including pharmaceuticals.
- Multidomain therapy should be the standard of care for AD.
- Multidomain interventions (also known as treatments) should be employed widely, early, and first-line.
Why it matters
This review of 23 studies reports that most completed trials of multidomain therapy showed benefit in at least one arm and argues this approach should be standard care. It is a review of existing trials, not new evidence, and does not establish that multidomain therapy cures or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort study
- Evidence strengthHigh
How this study scored 52/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular Neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Leroy Hood: h-index 167 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41275266) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-025-00912-2
- PubMed: 41275266
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Prevention trials from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.